Apex Laboratories Profile
Key Indicators
- Authorised Capital ₹ 2.75 Cr
- Paid Up Capital ₹ 1.83 Cr
- Company Age 46 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 136.87 Cr
- Satisfied Charges ₹ 469.16 Cr
- Revenue Growth -14.90%
- Profit Growth -81.50%
- Ebitda -71.04%
- Net Worth 5.85%
- Total Assets 7.09%
About Apex Laboratories
Apex Laboratories Private Limited (ALPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 15 July 1978 and has a history of 46 years and six months. Its registered office is in Chennai, Tamil Nadu, India.
The Corporate was formerly known as Apex Laboratories Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.75 Cr and a paid-up capital of Rs 1.83 Cr.
The company currently has active open charges totaling ₹136.87 Cr. The company has closed loans amounting to ₹469.16 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sulur Subramaniam, Srinivasan Murali, Sulur Vigneswaran, and Three other members serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85195TN1978PTC007554
-
Company No.
007554
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Jul 1978
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
What products or services does Apex Laboratories Private Limited offer?
Apex Laboratories Private Limited offers a wide range of products and services, including Surgical & ICU Equipments, Ventilator Parts & Consumables, Analyzers & Analytical Instruments, Elemental Analyzer, Industrial Air Conditioner & Devices, HVAC System, Urological & Obstetrics Instruments, Urinary Catheter, Common Disease Medicines, Pharmaceutical Medicine.
Who are the key members and board of directors at Apex Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sulur Subramaniam
|
Managing Director | 03-Feb-1982 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Srinivasan Murali
|
Director | 01-Sep-2022 | Current |
|
Sulur Vigneswaran
|
Whole-Time Director | 01-Oct-2012 | Current |
|
Swaminathan
|
Director | 03-Sep-1982 | Current |
|
Thangavelu Mannavan
|
Director | 14-May-2014 | Current |
|
Vishagan
|
Director | 11-Oct-2019 | Current |
Financial Performance of Apex Laboratories.
Apex Laboratories Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.9% decrease. The company also saw a substantial fall in profitability, with a 81.5% decrease in profit. The company's net worth moved up by a moderate rise of 5.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apex Laboratories?
In 2023, Apex Laboratories had a promoter holding of 95.24% and a public holding of 4.76%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Vanan Pharma Private LimitedSulur Subramaniam, Srinivasan Murali and 1 more are mutual person
-
Olympus Premedia Private LimitedSulur Subramaniam and Srinivasan Murali are mutual person
-
Apex Exports Private LimitedSrinivasan Murali and Vishagan are mutual person
-
Subramaniam Chemicals And Explosives Private LimitedSulur Subramaniam and Sulur Vigneswaran are mutual person
-
Halez Hospitality Services Private Limited
Sulur Subramaniam and Vishagan are mutual person
-
Soorya Apex Health Care Private Limited
Sulur Subramaniam is a mutual person
Charges (Loans)
₹136.87 Cr
₹469.16 Cr
Charges Breakdown by Lending Institutions
- Standard Chartered Bank : 93.91 Cr
- Axis Bank Limited : 31.00 Cr
- Hdfc Bank Limited : 6.05 Cr
- Others : 5.91 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Sep 2024 | Others | ₹2.31 Cr | Open |
| 24 Apr 2024 | Hdfc Bank Limited | ₹3.00 M | Open |
| 30 Oct 2023 | Axis Bank Limited | ₹2.53 M | Open |
| 28 Jul 2023 | Hdfc Bank Limited | ₹2.01 M | Open |
| 31 May 2023 | Standard Chartered Bank | ₹17.50 Cr | Open |
How Many Employees Work at Apex Laboratories?
Apex Laboratories has a workforce of 3464 employees as of Dec 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apex Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apex Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
